{"ok":true,"data":{"subject":{"kind":"trial","nctId":"NCT05633615","title":"Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma","sponsor":"SWOG Cancer Research Network","phases":["PHASE2"],"status":"RECRUITING","indication":null,"disease":"diffuse large B-cell lymphoma"},"rows":[{"n":1,"question":"Is the biology right?","flags":[{"id":"somatic_driver","label":"Somatic driver evidence","value":"yes","detail":"CD79B in diffuse large B-cell lymphoma","rule":"Open Targets has somatic-mutation evidence for the target in this cancer","source":{"label":"Open Targets: CD79B in diffuse large B-cell lymphoma","url":"https://platform.opentargets.org/evidence/ENSG00000007312/MONDO_0018905","date":"2026-11-11T22:10:50.504Z"},"context":[{"figure":"2.3× relative success for targets with somatic (IntOGen) support in oncology","dataset":"Minikel et al., Nature 2024","years":"drug programs to 2023","caveat":"A ratio between groups, not a probability for this program; mostly phase 2 to 3."}]},{"id":"human_genetic","label":"Human genetic evidence","value":"yes","detail":"CD79B: somatic","rule":"Any germline or somatic human genetic evidence for the target in this cancer, counted apart from animal-model and literature evidence","source":{"label":"Open Targets: CD79B in diffuse large B-cell lymphoma","url":"https://platform.opentargets.org/evidence/ENSG00000007312/MONDO_0018905","date":"2026-11-11T22:10:50.504Z"},"context":[{"figure":"2.6× relative probability of success, phase 1 to launch, with human genetic support","dataset":"Minikel et al., Nature 2024","years":"drug programs to 2023","caveat":"All therapy areas, mostly germline evidence; not a probability for this program."}]},{"id":"pediatric_target","label":"Pediatric target","value":"yes","detail":"CD19, CD79B on the FDA list","rule":"Target is on FDA's Pediatric Molecular Target List (relevant targets); membership alone neither requires nor waives a study","source":{"label":"FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01))","url":"https://www.fda.gov/media/191157/download?attachment","date":"2026-11-11T07:05:03Z"},"context":[]},{"id":"haematologic","label":"Haematologic cancer","value":"yes","detail":"Haematologic","rule":"From the indication, or the registry conditions when no indication matches","source":{"label":"ClinicalTrials.gov NCT05633615","url":"https://clinicaltrials.gov/study/NCT05633615","date":"2026-11-11T22:10:50.504Z"},"context":[{"figure":"Likelihood of approval from phase 1: 7.5% haematologic vs 4.6% solid","dataset":"BIO / Informa / QLS 2021","years":"2011–2020","caveat":"Population-level, not a prediction."}]}],"facts":[{"label":"Background therapy","text":"Cyclophosphamide, Fludarabine: standard agents, not counted in these flags."},{"label":"CD19 (via Axicabtagene Ciloleucel)","text":"Evidence types in diffuse large B-cell lymphoma: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc.","source":{"label":"Open Targets: CD19 in diffuse large B-cell lymphoma","url":"https://platform.opentargets.org/evidence/ENSG00000177455/MONDO_0018905","date":"2026-11-11T22:10:50.504Z"}},{"label":"CD3E (via Mosunetuzumab)","text":"Evidence types in diffuse large B-cell lymphoma: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc.","source":{"label":"Open Targets: CD3E in diffuse large B-cell lymphoma","url":"https://platform.opentargets.org/evidence/ENSG00000198851/MONDO_0018905","date":"2026-11-11T22:10:50.504Z"}},{"label":"CD3G (via Mosunetuzumab)","text":"Evidence types in diffuse large B-cell lymphoma: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc.","source":{"label":"Open Targets: CD3G in diffuse large B-cell lymphoma","url":"https://platform.opentargets.org/evidence/ENSG00000160654/MONDO_0018905","date":"2026-11-11T22:10:50.504Z"}},{"label":"CD3D (via Mosunetuzumab)","text":"Evidence types in diffuse large B-cell lymphoma: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc.","source":{"label":"Open Targets: CD3D in diffuse large B-cell lymphoma","url":"https://platform.opentargets.org/evidence/ENSG00000167286/MONDO_0018905","date":"2026-11-11T22:10:50.504Z"}},{"label":"CD79B (via Polatuzumab Vedotin)","text":"Evidence types in diffuse large B-cell lymphoma: literature, somatic_mutation, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, intogen, cancer_gene_census, eva_somatic, europepmc.","source":{"label":"Open Targets: CD79B in diffuse large B-cell lymphoma","url":"https://platform.opentargets.org/evidence/ENSG00000007312/MONDO_0018905","date":"2026-11-11T22:10:50.504Z"}},{"label":"TUBB4B (via Polatuzumab Vedotin)","text":"Evidence types in diffuse large B-cell lymphoma: clinical. Datasources: clinical_precedence.","source":{"label":"Open Targets: TUBB4B in diffuse large B-cell lymphoma","url":"https://platform.opentargets.org/evidence/ENSG00000188229/MONDO_0018905","date":"2026-11-11T22:10:50.504Z"}},{"label":"TUBB1 (via Polatuzumab Vedotin)","text":"Evidence types in diffuse large B-cell lymphoma: clinical. Datasources: clinical_precedence.","source":{"label":"Open Targets: TUBB1 in diffuse large B-cell lymphoma","url":"https://platform.opentargets.org/evidence/ENSG00000101162/MONDO_0018905","date":"2026-11-11T22:10:50.504Z"}}],"pending":[{"what":"Normal-tissue expression in vital organs","source":"Human Protein Atlas (ticket 36)"},{"what":"Pan-essential in cell lines","source":"DepMap (ticket 36)"},{"what":"Approved drug on this target","source":"Drugs@FDA (ticket 30)"}]},{"n":2,"question":"Can the result be trusted?","flags":[{"id":"randomised","label":"Randomised","value":"yes","detail":"Randomised allocation","rule":"Registry allocation field","source":{"label":"ClinicalTrials.gov NCT05633615","url":"https://clinicaltrials.gov/study/NCT05633615","date":"2026-11-11T22:10:50.504Z"},"context":[]},{"id":"small_denominator","label":"Small denominator","value":"no","detail":"396 planned; each patient moves a rate by 100 ÷ 396 = 0.3 points","rule":"Enrolment under 30; the arithmetic is shown, not a benchmark","source":{"label":"ClinicalTrials.gov NCT05633615","url":"https://clinicaltrials.gov/study/NCT05633615","date":"2026-11-11T22:10:50.504Z"},"context":[]},{"id":"primary_os","label":"Primary endpoint is overall survival","value":"no","detail":"Progression free survival (PFS)","rule":"A registered primary outcome measure names overall survival","source":{"label":"ClinicalTrials.gov NCT05633615","url":"https://clinicaltrials.gov/study/NCT05633615","date":"2026-11-11T22:10:50.504Z"},"context":[{"figure":"Non-OS primary endpoint: odds ratio 2.79 for a positive phase 3","dataset":"Otsuka 2021, 400 phase 3 oncology trials","years":"to 2020","caveat":"Shown with the next figure: a surrogate is easier to hit, and often a weak guide to survival."},{"figure":"52% of surrogate-to-OS correlations are low","dataset":"Prasad 2015","years":"published to 2014","caveat":"Shown with the figure above."}]},{"id":"results_overdue","label":"Results overdue","value":"no","detail":"Primary completion expected 2030-06-30; not yet due","rule":"Primary completion (actual) more than 12 months ago and no results posted to the registry","source":{"label":"ClinicalTrials.gov NCT05633615","url":"https://clinicaltrials.gov/study/NCT05633615","date":"2026-11-11T22:10:50.504Z"},"context":[]}],"facts":[],"pending":[{"what":"Treated and evaluable counts, assessor, confirmed response, follow-up and data cutoff","source":"Readout extraction (ticket 32)"},{"what":"Primary endpoint changed between registry versions","source":"Registry versions in the store (ticket 32)"}]},{"n":3,"question":"What must it beat?","flags":[],"facts":[],"pending":[{"what":"Control-arm result and approved therapies for the same segment, with label links","source":"Drugs@FDA, FDA labels and readouts (tickets 30, 32)"}]},{"n":4,"question":"Too crowded, or too late?","flags":[],"facts":[{"label":"Stopped on this target","text":"63 terminated, withdrawn or suspended trials of drugs against CD19; 3 give no reason. Reasons are quoted as the registry gives them on the target page.","source":{"label":"CD19: what already stopped","url":"/target/ENSG00000177455#stopped","date":"2026-11-11T22:10:50.542Z"}}],"pending":[{"what":"Programs on the target by phase and months behind the leader","source":"Programs and Drugs@FDA (ticket 33)"}]},{"n":5,"question":"Can it be approved, and stay approved?","flags":[{"id":"single_country","label":"Single-country","value":"yes","detail":"All 95 sites in United States","rule":"All listed sites are in one country; the share of US sites is shown","source":{"label":"ClinicalTrials.gov NCT05633615","url":"https://clinicaltrials.gov/study/NCT05633615?tab=locations","date":"2026-11-11T22:10:50.504Z"},"context":[]},{"id":"eu_pip","label":"EU paediatric investigation plan","value":"yes","detail":"EMA/PE/0000181993 (mosunetuzumab, Treatment of mature B-cell neoplasms): PM: decision on the application for modification of an agreed PIP, 8 Nov 2024; EMEA-001995-PIP01-16-M04 (lisocabtagene maraleucel, Treatment of B-lymphoblastic leukaemia/lymphoma;Treatment of mature B-cell neoplasms): PM: decision on the application for modification of an agreed PIP, 27 Oct 2023; EMEA-002010-PIP01-16-M03 (axicabtagene ciloleucel, Treatment of mature B-cell neoplasms): PM: decision on the application for modification of an agreed PIP, 13 Apr 2022; EMEA-002335-PIP01-18 (autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor (axicabtagene ciloleucel), Treatment of mantle cell lymphoma): W: decision granting a waiver in all age groups for all conditions or indications, 15 Aug 2018; +1 more","rule":"An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name","source":{"label":"EMA data download (dated snapshot)","url":"https://www.ema.europa.eu/en/documents/report/medicines-output-paediatric_investigation_plans-output-json-report_en.json","date":"2026-11-11T09:12:26Z"},"context":[]},{"id":"eu_orphan","label":"EU orphan designation","value":"yes","detail":"EU/3/14/1393 positive 16 Dec 2014: Treatment of diffuse large B-cell lymphoma; EU/3/15/1579 positive 11 Nov 2015: Treatment of follicular lymphoma; EU/3/21/2517 positive 12 Nov 2021: Treatment of follicular lymphoma; EU/3/18/2013 positive 16 Apr 2018: Treatment of diffuse large B-cell lymphoma; +8 more","rule":"An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status","source":{"label":"EMA data download (dated snapshot)","url":"https://www.ema.europa.eu/en/documents/report/medicines-output-orphan_designations-json-report_en.json","date":"2026-11-11T09:12:26Z"},"context":[]},{"id":"eu_authorised","label":"Authorised in the EU","value":"yes","detail":"Polivy: authorised since 16 Jan 2020, orphan medicine; Lunsumio: authorised since 3 Jun 2022, orphan medicine, conditional; Breyanzi: authorised since 4 Apr 2022; Yescarta: authorised since 23 Aug 2018, orphan medicine","rule":"An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file","source":{"label":"EMA data download (dated snapshot)","url":"https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json","date":"2026-11-11T09:12:26Z"},"context":[]},{"id":"fda_orphan","label":"FDA orphan designation","value":"not published","detail":"FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the link","rule":"Would be: an FDA orphan designation names the drug","source":{"label":"FDA orphan designations search","url":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/","date":""},"context":[]},{"id":"fda_ped_approval","label":"FDA pediatric oncology approval","value":"no","detail":"FDA's table lists no pediatric approval of Axicabtagene Ciloleucel, Lisocabtagene Maraleucel, Mosunetuzumab, Polatuzumab Vedotin","rule":"FDA's Pediatric Oncology Drug Approvals table names the drug","source":{"label":"FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03)","url":"https://www.fda.gov/about-fda/oncology-center-excellence/pediatric-oncology-drug-approvals","date":"2026-11-11T22:10:50.553Z"},"context":[]},{"id":"studies_under_18","label":"Registered studies open to children","value":"yes","detail":"8 interventional studies of Axicabtagene Ciloleucel, Lisocabtagene Maraleucel, Mosunetuzumab, Polatuzumab Vedotin include patients under 18; 7 are recruiting, not yet recruiting or active","rule":"The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age","source":{"label":"ClinicalTrials.gov search","url":"https://clinicaltrials.gov/search?intr=%22Axicabtagene+Ciloleucel%22+OR+%22Lisocabtagene+Maraleucel%22+OR+%22Mosunetuzumab%22+OR+%22Polatuzumab+Vedotin%22&aggFilters=ages%3Achild%2CstudyType%3Aint","date":"2026-11-11T22:10:50.564Z"},"context":[]}],"facts":[{"label":"Caveat","text":"Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where the sites are is a fact about the record, not a judgement of its quality."},{"label":"Rare pediatric disease voucher","text":"FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news.","source":{"label":"FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs","url":"https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/rare-pediatric-disease-designation-and-priority-review-voucher-programs","date":"2026-11-11"}}],"pending":[{"what":"Precedent approvals for target, modality and endpoint; accelerated-approval status","source":"Drugs@FDA and FDA accelerated-approval tables (ticket 30)"}]},{"n":6,"question":"Can the sponsor finish?","flags":[],"facts":[{"label":"Sponsor","text":"SWOG Cancer Research Network (academic or other)","source":{"label":"ClinicalTrials.gov NCT05633615","url":"https://clinicaltrials.gov/study/NCT05633615","date":"2026-11-11T22:10:50.504Z"}},{"label":"principal investigator","text":"Brian T Hess, SWOG Cancer Research Network","source":{"label":"Person page","url":"/person/Brian%20T%20Hess","date":"2026-11-11T22:10:50.504Z"}}],"pending":[{"what":"Filed cash, quarterly spend and the runway arithmetic","source":"SEC XBRL company facts (ticket 37)"},{"what":"Sponsor's completed vs stopped oncology trials and results-reporting record","source":"Registry, by company (ticket 37)"}]}],"limits":"Public records cannot show: sales forecasts; a probability of success for this asset; full deal terms and net prices; FDA designations and action dates before approval (shown only as company-reported); clinical holds unless the company disclosed them; manufacturing; patents on unapproved drugs; whether preclinical findings have been replicated.","sources":[{"label":"ClinicalTrials.gov NCT05633615","url":"https://clinicaltrials.gov/study/NCT05633615","date":"2026-11-11T22:10:50.504Z"},{"label":"Open Targets Platform","url":"https://platform.opentargets.org","date":"2026-11-11T22:10:50.504Z"},{"label":"FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01))","url":"https://www.fda.gov/media/191157/download?attachment","date":"2026-11-11T07:05:03Z"}]},"source":"ClinicalTrials.gov + Open Targets","fetchedAt":"2026-11-11T22:10:50.497Z"}